| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 367.34M | 289.72M | 250.32M | 208.89M | 193.91M |
| Gross Profit | 230.62M | 172.11M | 156.07M | 179.29M | 186.05M |
| EBITDA | 91.54M | 69.33M | 57.80M | 81.16M | 91.00M |
| Net Income | 65.16M | 53.00M | 43.38M | 61.44M | 69.01M |
Balance Sheet | |||||
| Total Assets | 6.97B | 5.81B | 5.71B | 5.67B | 5.50B |
| Cash, Cash Equivalents and Short-Term Investments | 1.03B | 792.76M | 725.61M | 771.30M | 1.73B |
| Total Debt | 644.29M | 544.95M | 529.94M | 309.51M | 255.94M |
| Total Liabilities | 6.28B | 5.27B | 5.22B | 5.22B | 4.96B |
| Stockholders Equity | 696.56M | 531.23M | 495.06M | 451.28M | 541.29M |
Cash Flow | |||||
| Free Cash Flow | 59.52M | 55.36M | 64.89M | 103.00M | 140.86M |
| Operating Cash Flow | 65.22M | 60.93M | 67.51M | 105.18M | 142.72M |
| Investing Cash Flow | -57.73M | 30.33M | -7.03M | -487.72M | -649.09M |
| Financing Cash Flow | -25.59M | 23.90M | -36.10M | 237.34M | 581.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $749.59M | 12.18 | 6.83% | 4.16% | 8.23% | -0.07% | |
69 Neutral | $681.89M | 9.81 | 14.51% | 3.09% | 4.29% | 10.56% | |
69 Neutral | $815.56M | 10.05 | 15.62% | 3.55% | -0.23% | 10.95% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | $666.86M | 7.29 | 14.41% | 2.93% | 47.65% | 101.00% | |
64 Neutral | $778.40M | 8.09 | 9.49% | 3.66% | 24.08% | 9.83% | |
61 Neutral | $785.04M | 12.77 | 7.31% | 2.58% | 12.09% | -15.97% |
On January 8, 2026, Camden National Corporation announced that its board of directors had authorized a new share repurchase program for up to 850,000 shares of its common stock, representing about 5% of its issued and outstanding shares as of December 31, 2025, with the program becoming effective on January 7, 2026. The repurchases, which may be conducted via open market purchases, accelerated share repurchase transactions, or privately negotiated deals under Rule 10b5-1 plans, are designed to provide the company with flexible capital management options and can be adjusted or suspended depending on market conditions, the company’s capital position, and internal capital generation, potentially affecting share liquidity and shareholder value.
The most recent analyst rating on (CAC) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Camden National stock, see the CAC Stock Forecast page.
On December 16, 2025, Camden National Corporation announced a quarterly dividend of $0.42 per share, resulting in an annualized yield of 3.68% based on the December 15, 2025 stock price. The dividend is set to be paid on January 30, 2026, to shareholders recorded by January 15, 2026, reflecting the company’s ongoing commitment to returning value to its investors.
The most recent analyst rating on (CAC) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Camden National stock, see the CAC Stock Forecast page.